IngentaConnect Lower plasma adiponectin concentration predicts the efficacy of p...

Authors: Hiramatsu, S.¹; Tajiri, Y.²; Karashima, T.¹

Source: Diabetes, Obesity and Metabolism, Volume 6, Number 3, May 2004 , pp. 231-233(3)

Abstract:

Aim:

To investigate clinical efficacy of pioglitazone in association with plasma adiponectin concentration in type 2 diabetic patients. Methods:

Ten diabetic patients were treated with 15 or 30 mg of pioglitazone for 8 weeks, and association between plasma adiponectin concentration before treatment and decrease in glycated albumin levels was examined. Results:

Treatment with pioglitazone for 8 weeks lowered glycated albumin level (27.1 ± 1.2 to 23.8 ± 1.4%, p < 0.05), and inverse relationship between changes in glycated albumin and plasma adiponectin concentration before treatment was revealed (r = −0.66, p < 0.05). Plasma adiponectin concentrations of patients whose glycated albumin level reduced by more than 10% of the levels before treatment were significantly lower than those of patients whose glycaemic control was affected less (5.2 ± 0.6 vs. 8.0 ± 1.0 µg/ml, p < 0.05). Conclusion:

Lower plasma adiponectin concentration predicts the clinical efficacy of pioglitazone.

Keywords: adiponectin; diabetes mellitus; diabetes treatment; insulin resistance

Document Type: Short communication

DOI: 10.1111/j.1462-8902.2004.00333.x

Affiliations: 1: Department of Metabolism and Endocrinology, Department of Clinical Research, National Kyushu Medical Centre, Fukuoka, Japan 2: Department of Metabolism and Endocrinology, Fukuoka Medical Association Hospital, Fukuoka, Japan

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.39 plus tax Refund Policy

Lower plasma adiponectin concentration predicts the efficacy of pioglitazone in diabetic patients